New Study: States Could Save Up to $1.8 Billion Annually by Prioritizing Lower-Cost Biosimilar Medicines
At a time when states across the country are grappling with significant budget challenges, a new study from the Center for Medical Economics and Innovation at the Pacific Research Institute – the nonpartisan, California-based, free market think tank – finds that state employee health plans could save up to $1.8 billion every year by making greater use of lower-cost biosimilars. Click to download the study, The Biosimilar Savings Opportunity: Prioritizing Biosimilars Will Generate Significant Savings ...
Unauthorized GLP-1 Knockoffs Risk Patient Safety and Future Innovation, New PRI Brief Warns
As federal regulators intensify enforcement against companies selling unauthorized knockoffs of blockbuster weight-loss drugs, a new Pacific Research Institute brief warns that the booming GLP-1 knockoff market is creating patient safety risks while undermining future breakthrough medicines. “GLP-1s are among the most promising medical breakthroughs in decades, helping patients struggling with diabetes, obesity and other chronic illnesses,” said Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation and the brief’s author. “But ...
Don’t Blame Breakthrough Drugs for Costs, Fix Hospital Market
America’s healthcare tab has hit a new record. According to federal data published late last month, national health expenditures climbed to nearly $5.7 trillion in 2025, an increase of 7.3% over the previous year. The report noted that retail prescription drug spending rose 11%, driven in part by increased use of GLP-1 medicines. Increases in health spending are not, by themselves, evidence that our system is failing. Read the op-ed here.
Trending Topics
Studies
